col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


117 Results       Page 1

 [1] 
Wiley: British Journal of Clinical Pharmacology
  original article Date Title Authors   All Authors
1 [GO] 2024―Jul―05 On the use of open-label studies for the evaluation of cannabis-based products for the treatment of long COVID Andriy A. Gorbenko, Adam A. Cohen
2 [GO] 2024―May―31 COVID-19 severity gradient differentially dysregulates clinically relevant drug processing genes in nasopharyngeal swab samples Chukwunonso K. Nwabufo, Jessica Luc, Allison McGeer, Jeremy Alexander Hirota, Samira Mubareka, Andrew C. Doxey, Theo J. Moraes
3 [GO] 2024―Apr―15 Physiologically-based pharmacokinetic modelling guided dose evaluations of nirmatrelvir/ritonavir in renal impairment for the management of COVID-19 Tat Ming Ng, Ziteng Wang, Eric Chun Yong Chan
4 [GO] 2024―Apr―09 OpenSAFELY: The impact of COVID-19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate Andrew D. Brown, Louis Fisher, Helen J. Curtis, Milan Wiedemann, William J. Hulme, Victoria Speed, et al. (+21)
5 [GO] 2024―Mar―31 Impact of the early COVID-19 pandemic on adult mental health-related dispensed medications, hospitalizations and specialist outpatient visits in Norway and Sweden: Interrupted time series analysis David Moreno-Martos, Jing Zhao, Huiqi Li, Fredrik Nyberg, Ludvig Daae Bjørndal, Mohammadhossein Hajiebrahimi, et al. (+7)
6 [GO] 2024―Feb―09 An artificial intelligence algorithm for co-clustering to help in pharmacovigilance before and during the COVID-19 pandemic Alexandre Destere, Giulia Marchello, Diane Merino, Nouha Ben Othman, Alexandre O. Gérard, Thibaud Lavrut, et al. (+5)
7 [GO] 2023―Dec―30 Clinical trials of pharmacological interventions for SARS-CoV-2 published in leading medical journals report adherence but not how it was assessed. C. Lee, A. Otunla, I. Brennan, J. K. Aronson, D. Nunan
8 [GO] 2023―Dec―18 Feasibility of a cannabidiol (CBD)-dominant cannabis-based medicinal product (CBMP) for the treatment of Long COVID symptoms: A single arm open-label feasibility trial Hannah Thurgur, Michael Lynskey, Anne Katrin Schlag, Carol Croser, David John Nutt, Elizabeth Iveson
9 [GO] 2023―Oct―31 Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2 H. E. Higham, L. Morgan, C. Cooper, J. Marshall, A. Mawer, S. Jackson, et al. (+5)
10 [GO] 2023―Oct―25 Examining the effectiveness and duration of adjuvanted versus non-adjuvanted influenza vaccines in protecting older adults against symptomatic SARS-CoV-2 infection Francesco Lapi, Alexander Domnich, Ettore Marconi, Alessandro Rossi, Ignazio Grattagliano, Claudio Cricelli
11 [GO] 2023―May―24 Menstrual abnormalities after COVID-19 vaccination in the Netherlands: a description of spontaneous and longitudinal patient-reported data J. W. Duijster, M. E. Schoep, T. E. Nieboer, R. Jajou, A. Kant, F. Van Hunsel
12 [GO] 2023―May―10 The impact of the COVID-19 pandemic on antibiotic consumption and prevalence of pathogens in primary and secondary healthcare settings in Northern Ireland Mamoon A. Aldeyab, William Crowe, Reema A. Karasneh, Lynsey Patterson, Muhammad Sartaj, Judith Ewing, et al. (+9)
13 [GO] 2023―Apr―14 Ensovibep, a SARS-CoV-2 antiviral DARPin, is safe and well tolerated in healthy volunteers: results of a first-in-human, ascending single-dose Phase 1 study Nina Stojcheva, Stacy Gladman, Marianne Soergel, Christof Zitt, Roxana Drake, Tony Lockett, et al. (+11)
14 [GO] 2023―Feb―15 Single dose tocilizumab for COVID-19 associated cytokine storm syndrome: less is more Niels W. Boone, Dirk Jan A. R. Moes, Sofia Ramiro, Remy L. M. Mostard, Cesar Magro-Checa, Christel M. P. van Dongen, et al. (+7)
15 [GO] 2023―Jan―31 A case series of Bacillus Calmette-Guérin scar reactivation after administration of both mRNA and viral vector COVID-19 vaccines Leontine van Balveren, Eugène P. van Puijenbroek, Linda Davidson, Florence van Hunsel
16 [GO] 2023―Jan―31 Efficacy and safety of regdanvimab in patients with mild to moderate COVID-19: A rapid review and meta-analysis Behnam Amani, Bahman Amani
17 [GO] 2022―Dec―15 Experience with Sotrovimab treatment of SARS-CoV-2 infected patients in Denmark Line Dahlerup Rasmussen, Anne-Mette Lebech, Anne Øvrehus, Birgitte Klindt Poulsen, Hanne Rolighed Christensen, Henrik Nielsen, et al. (+14)
18 [GO] 2022―Dec―10 Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 ICU patients Lorenzo G. R. Romano, Nicole G. M. Hunfeld, Marieke J. H. A. Kruip, Henrik Endeman, Tim Preijers
19 [GO] 2022―Dec―08 A Narrative Review of Vaccine Pharmacovigilance During Mass Vaccination Campaigns: Focus on Myocarditis and Pericarditis after COVID-19 mRNA Vaccination Pierre-Philippe Piché-Renaud, Shaun K. Morris, Karina A. Top
20 [GO] 2022―Nov―24 COVID-19 related medicine utilization study in pregnancy - the COVI-PREG cohort Guillaume Favre, Eva Gerbier, Emeline Maisonneuve, Léo Pomar, Ursula Winterfeld, Karine Lepigeon, et al. (+8)
21 [GO] 2022―Nov―12 Management of acquired hemophilia A in severe Covid-19: Hemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis Georg Gelbenegger, Ludwig Traby, Nina Rahimi, Paul Knöbl
22 [GO] 2022―Nov―02 Communication is Crucial: Lessons from COVID-19 vaccination and pregnancy Christine Cole, Maria Tsakiroglou, Catriona Waitt
23 [GO] 2022―Oct―27 COVID-19 restrictions and the incidence and prevalence of prescription opioid use in Australia - a nation-wide study Monica Jung, Dickson Lukose, Suzanne Nielsen, J. Simon Bell, Geoffrey I. Webb, Jenni Ilomäki
24 [GO] 2022―Oct―10 Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19 - a phase 2a, open-label, single dose escalation study Manon L. M. Prins, Johan L. van der Plas, Maurits F. J. M. Vissers, Cécile L. Berends, Gaby Tresch, Marianne Soergel, et al. (+10)
25 [GO] 2022―Oct―03 COVID-19: Clinical status of vaccine development till date Sunny Kumar, Malini Basu, Pratyasha Ghosh, Aafreen Ansari, Mrinal K. Ghosh
26 [GO] 2022―Sep―12 People exposed to proton pump inhibitors shortly preceding COVID-19 diagnosis are not at an increased risk of subsequent hospitalizations and mortality: a nation-wide matched cohort study Ivan Kodvanj, Jan Homolak, Vladimir Trkulja
27 [GO] 2022―Aug―30 Comparative assessment of viral dynamic models for SARS-CoV-2 for pharmacodynamic assessment in early treatment trials Akosua A. Agyeman, Tao You, Phylinda L. S. Chan, Dagan O. Lonsdale, Christoforos Hadjichrysanthou, Tabitha Mahungu, et al. (+6)
28 [GO] 2022―Aug―27 Prevalence of NSAID use among people with COVID-19 and the association with COVID-19 related outcomes: systematic review and meta-analysis M. D. Huilei Zhao, M. D. Shanshan Huang, M. D. Shan Huang, M. D. Fuwei Liu, B. D. Wen Shao, M. D. Kaibo Mei, et al. (+6)
29 [GO] 2022―Aug―25 Local Variation in Low Carbon Footprint Inhalers in Pre-COVID Pandemic Primary Care Prescribing Guidelines for Adult Asthma in England and its Potential Impact Adam J. Twigg, Alexander Wilkinson, James N. Smith
30 [GO] 2022―Aug―12 Systemic Exposure to Hydroxychloroquine and its relationship with outcome in severely ill COVID-19 patients in New York City Alex K. Lyashchenko, Yifan Yu, Donald J. McMahon, Robert Bies, Michael T. Yin, Serge Cremers
31 [GO] 2022―Jul―20 Recombinant protein subunit COVID-19 Vaccine Induced Guillain-Barre Syndrome in an adolescent: A case report Rachna Rohilla, Ashish Kumar Kakkar, Krishna Divyashree, Ritin Mohindra, Vikas Suri
32 [GO] 2022―Jul―13 Fluvoxamine for COVID-19 outpatients: For the time being, we might prefer to curb our optimism Vladimir Trkulja
33 [GO] 2022―Jun―28 Rapid Review and Meta-Analysis of Adverse Events Associated with Molnupiravir in Patients with COVID-19 Behnam Amani, Sara Zareei, Bahman Amani
34 [GO] 2022―May―28 Acute appendicitis in a patient immunised with COVID-19 vaccine: a case report with morphological analysis Ettore Marconi, Giada Crescioli, Roberto Bonaiuti, Lavinia Pugliese, Raffaella Santi, Gabriella Nesi, et al. (+3)
35 [GO] 2022―Apr―18 Erythema nodosum induced by Covid-19 Pfizer-BioNTech mRNA Vaccine: A case report and brief literature review Ferdaous Chahed, Najah Ben Fadhel, Haifa Ben Romdhane, Monia Youssef, Seifeddine Ben Hammouda, Amel Chaabane, et al. (+2)
36 [GO] 2022―Apr―16 Analgesia and COVID-19 William F. Laughey, Imran Lodhi, Olutoba Sanni, Graham Pennick, Bruce Charlesworth
37 [GO] 2022―Mar―31 Efficacy of pharmacological interventions in COVID-19: A network meta-analysis Sandhiya Selvarajan, Annuja Anandaradje, Santhosh Shivabasappa, Deepthy Melepurakkal Sadanandan, N. Sreekumaran Nair, Melvin George
38 [GO] 2022―Mar―24 Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials Innocent G. Asiimwe, Sudeep P. Pushpakom, Richard M. Turner, Ruwanthi Kolamunnage-Dona, Andrea L. Jorgensen, Munir Pirmohamed
39 [GO] 2022―Mar―10 Response to Dal-Ré and Holm's ethical concern regarding the UK PANORAMIC COVID-19 trial by the PANORAMIC Investigators Christopher C. Butler
40 [GO] 2022―Mar―02 Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it? Vladimir Trkulja
41 [GO] 2022―Feb―22 Ethical concern regarding the UK PANORAMIC COVID-19 trial Rafael Dal-Ré, Søren Holm
42 [GO] 2022―Feb―17 Association study between herpes zoster reporting and mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) Laure-Hélène Préta, Adrien Contejean, Francesco Salvo, Jean-Marc Treluyer, Caroline Charlier, Laurent Chouchana
43 [GO] 2022―Feb―08 Fluvoxamine for COVID-19 ICU patients? Vladimir Trkulja
44 [GO] 2022―Feb―05 Does metformin affect outcomes in COVID-19 patients with new or pre-existing diabetes mellitus? A systematic review and meta-analysis Adithan Ganesh, Michael D. Randall
45 [GO] 2022―Feb―02 Can nebulised HepArin Reduce morTality and time to Extubation in Patients with COVID-19 Requiring invasive ventilation Meta-Trial (CHARTER-MT): Protocol and Statistical Analysis Plan for an investigator-initiated international meta-trial of prospective randomised clinical studies Frank M. P. Haren, John G. Laffey, Antonio Artigas, Clive Page, Marcus J. Schultz, David Cosgrave, et al. (+12)
46 [GO] 2022―Jan―11 Pharmacokinetic characterization of favipiravir in patients with COVID-19 Rezzan Gülhan, Emel Eryüksel, Medine Gülçebi İdriz Oğlu, Yekta Çulpan, Aylin Toplu, Derya Kocakaya, et al. (+17)
47 [GO] 2022―Jan―05 Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients Frank M. P. Haren, Lex M. Loon, Anne Steins, Thomas L. Smoot, Caitlin Sas, Sabrina Staas, et al. (+19)
48 [GO] 2021―Dec―29 Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients Charlotte D. C. C. Heijden, Rob Heine, Emma J. Kooistra, Roger J. Brüggemann, Jesper W. J. Walburgh Schmidt, Elke P. L. M. Grouw, et al. (+3)
49 [GO] 2021―Dec―22 Association of Renin-Angiotensin-Aldosterone System inhibition with Covid-19 hospitalization and all-cause mortality in the UK Biobank Fatemeh Safizadeh, Thi Ngoc Mai Nguyen, Hermann Brenner, Ben Schöttker
50 [GO] 2021―Dec―10 Comment on “A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccine” Sotaro Ozaka, Takashi Kobayashi, Kazunari Murakami
51 [GO] 2021―Nov―22 Coping with COVID: preparing prescribers during the pandemic Robin E. Ferner, Julie Mason, Hannah K. Vallance, Tanvi Choudhary, John F. Marriott, Jamie J. Coleman, Sarah K. Pontefract
52 [GO] 2021―Nov―01 Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls Martina Calusic, Robert Marcec, Lea Luksa, Ivan Jurkovic, Natasa Kovac, Slobodan Mihaljevic, Robert Likic
53 [GO] 2021―Oct―29 Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials Driton Vela, Zana Vela-Gaxha, Mjellma Rexhepi, Rozafa Olloni, Violeta Hyseni, Rajmonda Nallbani
54 [GO] 2021―Sep―24 Combination therapies for COVID-19: an overview of the clinical trials landscape Sola Akinbolade, Diarmuid Coughlan, Ross Fairbairn, Glenn McConkey, Helen Powell, Dapo Ogunbayo, Dawn Craig
55 [GO] 2021―Sep―12 Preparation for the next pandemic-A plea for a nationalized approach Adam Cohen
56 [GO] 2021―Aug―23 A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccine Talia Walter, Saxon Connor, Catherine Stedman, Matthew Doogue
57 [GO] 2021―Aug―19 Promoting COVID-19 vaccination through music and drama-Lessons from early phase of the pandemic Bernard Appiah, Bhavneet Walia, Su Hyun Nam
58 [GO] 2021―Aug―18 Changes in antibiotic prescribing following COVID-19 restrictions: Lessons for post-pandemic antibiotic stewardship Malcolm B. Gillies, David P. Burgner, Lorraine Ivancic, Natasha Nassar, Jessica E. Miller, Sheena G. Sullivan, et al. (+4)
59 [GO] 2021―Aug―03 Development, evaluation and use of COVID-19 vaccines in older adults: Preliminary principles for the pandemic and beyond Sarah N. Hilmer, Mirko Petrovic, David G. Le Couteur, Janice B. Schwartz, Petra Thuermann
60 [GO] 2021―Jul―28 COVID-19 Acute Respiratory Distress Syndrome (ARDS): a Simulation Study of the Effects of Combination Therapy with Tocilizumab and Siltuximab Eileen B. Doyle, Darren Bentley, Michael G. Dodds
61 [GO] 2021―Jul―23 Science fiction has become reality: best practice for future viral pandemics Daniel F. B. Wright, Carl M. J. Kirkpatrick
62 [GO] 2021―Jul―17 Traditional medicines for COVID-19: Perspectives from clinical pharmacologists Getnet Yimer, Edmund Ekuadzi, Pius Fasinu, Andreia Cristina Melo, Goonaseelan (Colin) Pillai
63 [GO] 2021―Jun―26 Challenge in treating COVID-19 associate pulmonary aspergillosis: Supratherapeutic voriconazole levels Pinar Bakir Ekinci, Emre Kara, Ahmet Gorkem Er, Ahmet Cagkan Inkaya, Kutay Demirkan, Omrum Uzun
64 [GO] 2021―Jun―08 Cardiovascular drugs and COVID-19 clinical outcomes: a living systematic review and meta-analysis Innocent G. Asiimwe, Sudeep Pushpakom, Richard M. Turner, Ruwanthi Kolamunnage-Dona, Andrea L. Jorgensen, Munir Pirmohamed
65 [GO] 2021―May―15 Real life Study on the Pharmacokinetic of Remdesivir in ICU patients admitted for Severe COVID-19 Pneumonia Silvia Corcione, Amedeo De Nicolò, Giorgia Montrucchio, Silvia Scabini, Valeria Avataneo, Chiara Bonetto, et al. (+8)
66 [GO] 2021―May―13 Interferon-α-2b Aerosol Inhalation is Associated with Improved Clinical Outcomes in Patients with Coronavirus Disease-2019 Jiong Yu, Xuan Lu, Ling Tong, Xiaowei Shi, Jing Ma, Feifei Lv, et al. (+5)
67 [GO] 2021―Apr―28 Antihypertensive Medications and COVID-19 Diagnosis and Mortality: Population-based Case-Control Analysis in the United Kingdom Emma Rezel-Potts, Abdel Douiri, Phil J. Chowienczyk, Martin C. Gulliford
68 [GO] 2021―Apr―26 Prior use of therapeutic anticoagulation does not protect against COVID-19 related clinical outcomes in hospitalized patients: a propensity score-matched cohort study Janneke P. Spiegelenberg, Marleen M. H. J. Gelder, Martje L. Maas, Marcel M. C. Hovens, Anne Esselink, Anton S. M. Dofferhoff, et al. (+11)
69 [GO] 2021―Apr―23 Rethinking the role of Research Ethics Committees in the light of Regulation (EU) No 536/2014 on Clinical Trials and the COVID-19 pandemic Silvia Tusino, Maria Furfaro
70 [GO] 2021―Apr―23 Ethics of vaccination: should capability measures be used to inform SARS-CoV-2 vaccination strategies ? Michael R. Millar, Yannis Gourtsoyannis, Angelina Jayakumar
71 [GO] 2021―Apr―15 Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios Yawen Jiang, Dan Cai, Daqin Chen, Shan Jiang, Lei Si, Jing Wu
72 [GO] 2021―Apr―15 BLUEPRINT FOR PANDEMIC RESPONSE: FOCUS ON TRANSLATIONAL MEDICINE, CLINICAL PHARMACOLOGY, AND PHARMACOMETRICS Jasmine Davda, Kellie Reynolds, John D. Davis, Patrick F. Smith
73 [GO] 2021―Apr―13 SARS-CoV-2 mutations: A strain on efficacy of neutralizing monoclonal antibodies? Marko Boskovic, William Migo, Robert Likic
74 [GO] 2021―Mar―25 Liver and kidney function in patients with Covid-19 treated with remdesivir Sylvia A. Laar, Mark G. J. Boer, Kim B. Gombert-Handoko, Henk-Jan Guchelaar, Juliette Zwaveling
75 [GO] 2021―Mar―24 Will AstraZeneca be able to provide clinical trial data on its COVID-19 vaccine efficacy in older adults? Rafael Dal-Ré
76 [GO] 2021―Mar―20 Zinc supplementation as an adjunct therapy for COVID-19: challenges and opportunities Vidyasagar Chinni, Hanna El-Khoury, Marlon Perera, Rinaldo Bellomo, Daryl Jones, Damien Bolton, et al. (+2)
77 [GO] 2021―Mar―09 Intestinal SGLT1 as a therapeutic target in COVID-19-related diabetes: A “two-edged sword” hypothesis Theocharis Koufakis, Symeon Metallidis, Pantelis Zebekakis, Kalliopi Kotsa
78 [GO] 2021―Feb―20 Dexamethasone use and Mortality in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study Nicolas Hoertel, Marina Sánchez-Rico, Raphaël Vernet, Nathanaël Beeker, Antoine Neuraz, Jesús M. Alvarado, et al. (+9)
79 [GO] 2021―Feb―20 Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action Lakshmikirupa Sunderesan, Suvendu Giri, Himanshi Singh, Suvro Chatterjee
80 [GO] 2021―Feb―13 Postvaccination anaphylaxis and mRNA-based SARS-CoV-2 vaccines-Much ado about nothing? Robert Marcec, Robert Likic
81 [GO] 2021―Jan―28 No association between use of ACE inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) study Roos S.G. Sablerolles, Freija E.F. Hogenhuis, Melvin Lafeber, Bob P.A. Loo, Sander D. Borgsteede, Eric Boersma, et al. (+2)
82 [GO] 2020―Dec―30 INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and Statistical Analysis Plan for an investigator-initiated international meta-trial of randomised studies Frank M.P. Haren, Alice Richardson, Hwan-Jin Yoon, Antonio Artigas, John G. Laffey, Barry Dixon, et al. (+23)
83 [GO] 2020―Dec―30 Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: An example in SARS-CoV-2 Kashyap Patel, Michael Dodds, Antonio Gonçalves, Mohamed A. Kamal, Craig R. Rayner, Carl M. Kirkpatrick, Patrick F. Smith
84 [GO] 2020―Dec―18 A possible increased risk of metamizole-associated neutropenia among COVID-19 patients Tsahi T. Lerman, Moshe Sagi, Yair Shafir, Liron Sheena, Eytan Cohen, Elad Goldberg, Ilan Krause
85 [GO] 2020―Dec―02 Racing to immunity: Journey to a COVID-19 vaccine and lessons for the future Ester Calvo Fernández, Lucie Y. Zhu
86 [GO] 2020―Nov―27 Clinical studies assessing the efficacy, effectiveness, and safety of remdesivir in management of COVID-19: a scoping review Juan Pimentel, Cassandra Laurie, Anne Cockcroft, Neil Andersson
87 [GO] 2020―Nov―24 Pharmacokinetics under the COVID-19 Storm Venkatesh Pilla Reddy, Eman El-Khateeb, Heeseung Jo, Natalie Giovino, Emily Lythgoe, Shringi Sharma, et al. (+3)
88 [GO] 2020―Nov―21 Chasing COVID-19 chemotherapeutics without putting the cart before the horse Steven P. Rannard, Tom O. McDonald, Andrew Owen
89 [GO] 2020―Nov―21 Comparison of Infection Risks and Clinical Outcomes in Patients with and without SARS-CoV-2 Lung Infection under Renin-Angiotensin-Aldosterone-System Blockade - Systematic Review and Meta-Analysis Chang Chu, Shufei Zeng, Ahmed A. Hasan, Carl-Friedrich Hocher, Bernhard K. Kraemer, Berthold Hocher
90 [GO] 2020―Nov―13 Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs Sara Ferraro, Marco Tuccori, Irma Convertino, Giulia Valdiserra, Emiliano Cappello, Fabrizio Maggi, et al. (+2)
91 [GO] 2020―Oct―30 Risk Assessment of therapeutic agents under consideration to treat COVID-19 in Pediatric Patients and Pregnant Women Jeffrey S. Barrett
92 [GO] 2020―Oct―29 Challenges of drug development during the COVID-19 pandemic: key considerations for clinical trial designs Jun Shi, Yubo Xiao, Yiting Zhang, Donghao Geng, Danhua Cong, Kevin X. Shi, Richard J. Knapp
93 [GO] 2020―Oct―24 Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population - a Danish cohort study Bente Mertz Nørgård, Jan Nielsen, Torben Knudsen, Rasmus Gaardskær Nielsen, Michael Due Larsen, Line Riis Jølving, Jens Kjeldsen
94 [GO] 2020―Oct―21 Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis Rajith K.R. Rajoli, Henry Pertinez, Usman Arshad, Helen Box, Lee Tatham, Paul Curley, et al. (+17)
95 [GO] 2020―Oct―14 COVID-19 vaccines: the importance of transparency and fact-based education Adam F. Cohen, Joop Gerven, Juan Garcia Burgos, Anthonius Boer, Ron A. M. Foucher, H. Flore, et al. (+4)
96 [GO] 2020―Oct―13 Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic Daniela R. Junqueira, Brian H. Rowe
97 [GO] 2020―Sep―22 A PHARMACOLOGICAL FRAMEWORK FOR INTEGRATING TREATING THE HOST, REPURPOSING AND THE DAMAGE RESPONSE FRAMEWORK IN COVID-19 Jennifer Martin, Richard Head
98 [GO] 2020―Sep―03 Beyond Dexamethasone, Emerging Immuno-Thrombotic Therapies for COVID-19 Melanie Peta Jensen, Marc George, Derek Gilroy, Reecha Sofat
99 [GO] 2020―Aug―31 Supporting frontline clinicians in the time of the pandemic: Rapid response pharmacology team Karin B. Mirzaev, Yury Kiselev, Dmitriy V. Ivashchenko, Vitaly Otdelenov, Dmitry A. Sychev
100 [GO] 2020―Aug―25 Lessons for teaching from the pandemic Jan Strojil, Hana Suchánková
101 [GO] 2020―Aug―21 Prescribing in COVID-19 patients: Should we take into account inflammation? Catia Marzolini, Manuel Battegay, Parham Sendi, David J. Back
102 [GO] 2020―Aug―17 The COVID-19 Ibuprofen controversy; a systematic review of NSAIDs in adult acute lower respiratory tract infections Ricky Vaja, Jeffery Chan, Plinio Ferreira, Amer Harky, Luke J. Rogers, Hime H. Gashaw, et al. (+2)
103 [GO] 2020―Jul―21 ABNORMAL LABORATORY FINDINGS AND PLASMA CONCENTRATION MONITORING OF LOPINAVIR AND RITONAVIR IN COVID-19 Benjamin Batteux, Sandra Bodeau, Valérie Gras-Champel, Sophie Liabeuf, Jean-Philippe Lanoix, Jean-Luc Schmit, et al. (+6)
104 [GO] 2020―Jul―21 Model-Informed Drug Repurposing: Viral Kinetic Modeling to Prioritize Rational Drug Combinations for COVID-19 Michael G. Dodds, Rajesh Krishna, Antonio Goncalves, Craig R. Rayner
105 [GO] 2020―Jul―18 Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19 Ricardo Peña-Silva, Stephen B. Duffull, Andrew C. Steer, Sandra X. Jaramillo-Rincon, Amanda Gwee, Xiao Zhu
106 [GO] 2020―Jul―15 The impact of the global COVID-19 pandemic on the conduct of clinical trials. Return to normalcy by considering the practical impact of a structured ethical analysis Maurits F.J.M. Vissers, Adam F. Cohen, Joop M.A. Gerven, Geert Jan Groeneveld
107 [GO] 2020―Jul―13 Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials Emma H. Baker, Kamal Patel, Jonathan Ball, Sarah Edwards, Thomas S. Harrison, Arvind Kaul, et al. (+5)
108 [GO] 2020―Jul―08 Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19 Milo Gatti, Michele Fusaroli, Paolo Caraceni, Elisabetta Poluzzi, Fabrizio De Ponti, Emanuel Raschi
109 [GO] 2020―Jul―06 Potential role of IL-17 blocking agents in the treatment of severe COVID-19? Vedrana Bulat, Mirna Situm, Marija Delas Azdajic, Robert Likic
110 [GO] 2020―Jun―19 Model informed dosing of Hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and Gaps Pauline Thémans, Nicolas Dauby, Loïc Schrooyen, Faustine Lebout, Marc Delforge, Rakan Nasreddine, et al. (+9)
111 [GO] 2020―Jun―19 How to expedite early phase SARS-CoV-2 vaccine trials in pandemic setting - a practical perspective J.L. Plas, M. Roestenberg, A.F. Cohen, I.M.C. Kamerling
112 [GO] 2020―Jun―09 A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments Emma H. Baker, Danijela Gnjidic, Carl M.J. Kirkpatrick, Munir Pirmohamed, Daniel F.B. Wright, Anna Y. Zecharia
113 [GO] 2020―May―08 Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic Ahmet Emre Eşkazan
114 [GO] 2020―May―08 COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions David Back, Catia Marzolini, Catherine Hodge, Fiona Marra, Alison Boyle, Sara Gibbons, et al. (+2)
115 [GO] 2020―May―02 Off-target ACE2 ligands: possible therapeutic option for CoVid-19? Simone Brogi, Vincenzo Calderone
116 [GO] 2020―Apr―30 COVID-19 and (hydroxy)chloroquine-Azithromycin combination: Should we take the risk for our patients? Hervé Javelot, Wissam El-Hage, Guillaume Meyer, Guillaume Becker, Bruno Michel, Coraline Hingray
117 [GO] 2020―Apr―18 Dosing will be a key success factor in repurposing antivirals for COVID-19 Patrick F. Smith, Michael Dodds, Darren Bentley, Karen Yeo, Craig Rayner
 [1] 

117 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.011 sec